Education
About Us
Working with TipRanks
Follow Us
Astria Therapeutics (ATXS)
NASDAQ:ATXS
ATXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.73 - $16.90
Previous CloseN/A
Volume35.54K
Average Volume (3M)251.82K
Market Cap
$365.13M
Enterprise Value$393.28M
Total Cash (Recent Filing)$15.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.97
Next Earnings
May 08, 2025EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.09
Shares Outstanding56,434,220
10 Day Avg. Volume299,394
30 Day Avg. Volume251,819
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
$26.29Price Target Upside295.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Astria Therapeutics News
See All ATXS News
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe initiation of the Phase 3 ALPHA-ORBIT trial with navenibart for hereditary angioedema (HAE) presents a promising prophylactic therapy.
Financial StabilityAstria ended the quarter financially strong with $328.1 million in cash, which management believes will be sufficient to fund its current operating plan into mid-2027.
Bears Say
Cash BurnAnnualized cash burn is significant, with a burn rate of $117 million and approximately 2.5 years of cash remaining.
---
Ownership Overview
11.96% Insiders
18.59% Mutual Funds
<0.01% Other Institutional Investors
59.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATXS FAQ
What was Astria Therapeutics’s price range in the past 12 months?
Astria Therapeutics lowest stock price was $5.73 and its highest was $16.90 in the past 12 months.
What is Astria Therapeutics’s market cap?
Astria Therapeutics’s market cap is $365.13M.
When is Astria Therapeutics’s upcoming earnings report date?
Astria Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 55 days.
How were Astria Therapeutics’s earnings last quarter?
Astria Therapeutics released its earnings results on Mar 11, 2025. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.452 by $0.012.
Is Astria Therapeutics overvalued?
According to Wall Street analysts Astria Therapeutics’s price is currently Undervalued.
Does Astria Therapeutics pay dividends?
Astria Therapeutics does not currently pay dividends.
What is Astria Therapeutics’s EPS estimate?
Astria Therapeutics’s EPS estimate is -0.48.
How many shares outstanding does Astria Therapeutics have?
Astria Therapeutics has 56,434,220 shares outstanding.
What happened to Astria Therapeutics’s price movement after its last earnings report?
Astria Therapeutics reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.452. Following the earnings report the stock price went up 11.168%.
Which hedge fund is a major shareholder of Astria Therapeutics?
Currently, no hedge funds are holding shares in ATXS
---
Astria Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.29 (295.93% Upside)
$26.29 (295.93% Upside)
Blogger Sentiment
Bullish
ATXS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 78.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.69%
12-Months-Change
Fundamentals
Return on Equity
-38.03%
Trailing 12-Months
Asset Growth
86.55%
Trailing 12-Months
Company Description
Astria Therapeutics
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.
---
ATXS Stock 12 Month Forecast
Average Price Target
$26.29
▲(295.93% Upside)
Technical Analysis
Sangamo Biosciences
―
ProQR
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering ATXS
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+16.02%
reiterated a buy rating 7 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +16.02% per trade.
---